[144] PUMA BIOTECHNOLOGY INC SEC Filing

Rhea-AI Filing Summary

Puma Biotechnology Inc. (PBYI) – Form 144 Filing Overview

The filing discloses a proposed sale of 25,592 common shares under Rule 144. The shares were acquired through restricted-stock vesting on 07 Jul 2025 and are slated for sale on, or around, 08 Jul 2025. Based on the stated aggregate market value of $90,424.21, the implied average sale price is roughly $3.53 per share.

The planned sale represents approximately 0.05 % of Puma’s 49.64 million shares outstanding, indicating an immaterial dilution effect. No other sales by the same person were reported in the past three months, and the filer certifies there is no undisclosed material adverse information.

Key takeaways for investors

• Rule 144 provides an advance notice of insider disposition, offering transparency into potential trading activity.
• The transaction size is modest in dollar and percentage terms, suggesting limited market impact.
• The shares stem from equity compensation rather than open-market purchases, so the sale may simply serve personal liquidity needs rather than signal a strategic shift.

Positive

• Transparent advance disclosure of insider sale under Rule 144 gives investors visibility into upcoming trading activity.
• No additional insider sales in the past three months, reducing concerns about a broader sell-off.

Negative

• Insider disposition, even if small, can be perceived as a modestly negative sentiment signal toward the company’s near-term prospects.

Insights

Securities Analyst

TL;DR – Insider plans to sell 25.6k shares (~$90k), only 0.05 % of float; negligible dilution and limited market impact.

The Form 144 reveals a routine disposition of recently vested restricted stock. While insider selling can sometimes raise sentiment concerns, the dollar amount and share count are de minimis relative to Puma’s capitalization. The orderly disclosure under Rule 144 and absence of other recent sales mitigate any negative signal. I view the filing as neutral; it does not alter the fundamental outlook or valuation for PBYI.

Corporate Governance Expert

TL;DR – Transparent Rule 144 notice, small transaction, governance standards met; no red flags.

From a governance perspective, the filer has complied with disclosure requirements, affirming no non-public adverse information. The lack of aggregated sales and confirmation of compensation-related acquisition align with best practices. Given the scale, the filing is not impactful to shareholders’ rights or voting power. Overall impact is neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	25592	90424.21	49638093	07/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/07/2025	Restricted Stock Vesting	Issuer			25592	07/07/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Puma Biotechnology (PBYI) shares are being sold under this Form 144?

The filing covers 25,592 common shares.

What is the approximate market value of the planned sale?

The aggregate market value disclosed is $90,424.21.

When are the shares expected to be sold?

The filer lists an approximate sale date of 08 Jul 2025.

What percentage of Puma Biotechnology’s shares outstanding does this sale represent?

About 0.05 % of the 49.64 million shares outstanding.

Were there any other insider sales in the last three months?

The filing states "Nothing to Report" for prior three-month sales by the same person.